Loading patent…
AssigneesThe Kitasato Institute, Lipoprotein Research Stockholm AB
InventorsHiroshi Tomoda, Tohru Nagamitsu, Satoshi Omura, Paolo Parini, Osman Ahmed, Matteo Pedrelli, Camilla Pramfalk, Mats Eriksson
Estimating the term…
A low-molecular weight compound having an activity of inhibiting the functions of proprotein convertase subtilisin/kexin type 9 (PCSK9), a PCSK9 inhibitor containing a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active component, and a medicament containing the PCSK9 inhibitor as an active component for use in prevention or treatment of one or more symptoms, diseases, or disorders, related to the functions of PCSK9.
-8. (canceled)
An in vivo method of treating a disorder selected from the group consisting of hypercholesterolemia, familial hypercholesterolemia, hyperlipidemia, arteriosclerosis, and fatty liver in a mammal in need thereof, the method comprising administering to the mammal an effective amount of a compound selected from the group consisting of 1,11-O-o-methylbenzylidene-7-O-p-cyanobenzoyl-1,7,11-trideacetyl pyripyropene A (PRD125), 7-p-cyanobenzoyl-7-deacetyl pyripyropene A (PRD017), and 7-O-p-cyanobenzoyl-1,11-di(O-isobutyryl)-1,7,11-trideacetyl pyripyropene A (PRD056), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active component, wherein the administering inhibits the functions of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the mammal.
Dependencies are inferred from the claim text.